Premium
IN VITRO ACTIVITY OF CEFTAZIDIME, CEFOTAXIME AND GENTAMICIN AGAINST 11,521 CLINICAL ISOLATES OF BACTERIA
Author(s) -
Steinbakk MARTIN,
Midtvedt TORE,
Lingaas EGIL,
Gardsjord GUNNHILD
Publication year - 1987
Publication title -
acta pathologica microbiologica scandinavica series b: microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0108-0180
DOI - 10.1111/j.1699-0463.1987.tb03135.x
Subject(s) - ceftazidime , cefotaxime , gentamicin , microbiology and biotechnology , cephalosporin , aminoglycoside , chemistry , antibiotics , biology , bacteria , pseudomonas aeruginosa , genetics
The in vitro activity of ceftazidime has been compared with those of another third‐generation cephalosporin, cefotaxime, and the aminocyclitol aminoglycoside, gentamicin. A total of 11,521 clinical isolates of aerobic bacteria were employed, and an agar diffusion method was used for sensitivity testing. The MIC‐values were calculated from regression lines. The mean inhibition zones for ceftazidime against Gram‐positive organisms were significantly less than those against Gram‐negative isolates (23 mm vs. 33 mm, p<0.0001). Cefotaxime inhibited 74.0%, gentamicin 66.3% and ceftazidime 20.4% of the Grampositive isolates at a concentration of ≤ 2 mg/ml. Ceftazidime and cefotaxime were equally active against fermentative Gram‐negative rods, inhibiting 92.7% of each of these isolates at 2 mg/l. Against Ps. aeruginosa , ceftazidime (MIC 90 2.2 mg/l) was found to be almost as active as gentamicin (MIC 90 1.2 mg/l), and far more active than cefotaxime (MIC 90 434 mg/l). Gentamicin was the most active agent against Acinetobacter sp. (MIC 90 6.0 mg/l), followed by ceftazidime (MIC 90 18 mg/l) and cefotaxime (MIC 90 83 mg/l).